FDA expedites review of Biogen's multiple sclerosis drug

07/8/2009 | American City Business Journals

The FDA granted fast-track designation to Biogen Idec's PEGylated interferon beta-1a, a multiple sclerosis medicine. The drug's potential to treat patients with only one or two injections a month might have been a factor in the agency's decision. Biogen plans on "working closely with the FDA to expedite the compound's development and review process," a company official said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC